Additional Chromosomal Abnormalities in Chronic Myeloid Leukemia Patient Treated with First-Line Tyrosine Kinase Inhibitor Therapy: Good or Poor Prognosis?
Keywords:
chronic myeloid leukemia, additional chromosomal abnormalities, drug resistanceAbstract
A 33-year-old male came to Policlinic of Hematology-Medical Oncology Dr. Cipto Mangunkusumo General Hospital for routine control of chronic myeloid leukemia (CML) treatment. He was treated with Imatinib Mesylate (IM) for two years. At the beginning of therapy, he showed good treatment response. However, after two years of treatment, he lost complete hematological response (CHR) occured and major molecular response (MMR) was not achieved. This demonstrated drug resistance even with good compliance. Evaluation of therapy through cytogenetic karyotype testing showed complex additional chromosomal abnormalities (ACA) in addition to the Philadelphia chromosome (Ph). Tyrosine kinase inhibitor (TKI) therapy in this type of patients should be replaced with other alternative TKIs. A mutation profiling test is needed to determine alternative TKI. Monitoring in the treatment of CML patients is very important. The presence of ACA indicates disease progression and poor prognosis. Time to change therapy in CML patients must be done appropriately based on the results of hematological, molecular, and cytogenetic testing.References
Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. Lancet. 2007;370(9584):342-50.
Hoffmann VS, Baccarani M, Hasford J, et al. Treatment and outcome of 2904 CML patients from the EUTOS population-based registry. Leukemia. 2017;31(3):593.
Au WY, Caguoia PB, Chuah C, et al. Chronic myeloid leukemia in Asia. Int J Hematol. 2009;89:14–23.
Rajabto W, Reksodiputro AH, Tadjoedin H, Harimurti K. Hubungan gambaran klinis dan laboratorium hematologis antara leukemia granulositik kronik Ph(+)/BCR-ABL(+) dengan bentuk kelainan Ph/BCR-ABL lainnya. Jurnal Penyakit Dalam Indonesia. 2018;5(1):11-6.
Hochhaus A, Saussele S, Rosti G, et al. Chronic myeloid leukemia: ESMO clinical practice guidelines for diagnosis, treatment, and follow up. Ann Oncol. 2017;28 (Suppl 4):iv41-iv51.
Radich JP, Deininger M, Abboud CN, et al. Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology. J Nat Comprehensive Cancer Network. 2018;16(9):1108-35.
Jabbour E, Kantarjian H. Chronic myeloid leukemia. Chronic myeloid leukemia: 2018 update on diagnosis, therapy, and monitoring. Am J Hematol. 2018;93:442-59.
Crisan AM, Coriu D, Arion C, Colita A, Jardan C. The impact of additional cytogenetic abnormalities at diagnosis and during therapy with TKI in CML. J Med and Life. 2015;8(4):502-8.
Chandran RK, Geetha N, Sakthivel KM, et al. Impact of additional chromosome abberation on the disease progression of chronic myeloid leukemia. Front. Oncol. 2019;9(88):1-12.
Dorfman LE, Floriani MA, Oliveira TMRDR, et al. The role of cytogenetics and molecular biology in the diagnosis, treatment, and monitoring of patients with chronic myeloid leukemia. J Pras Pathol Med Lab. 2018;54(2);83-91.
Shah J. The importance of hematologic, cytogenetic, and molecular testing and mutational analysis in chronic myeloid leukemia. JCSO. 2014;121:179-87.
Vigil CE, Griffiths EA, Wang ESWetzler M. Interpretation of cytogenetic and molecular results in patients treated for CML. Blood Rev. 2011;25(3):139-46.
Hughes T, White D. Which TKI? AN embarrassment of riches for chronic myeloid leukemia patients. Hematology. 2013:168-75.
Bitencourt R, Zalcberg I, Louro ID. Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia. Rev Bras Hematol Hemoter. 2011;33(6):470-5.
Bhamidipati P, Kantarjian H, Cortes J, Cornelison AM, Jabbour E. Management of imatinib-resistant patients with chronic myeloid leukemia. Ther adv Hematol 2013;4(2):103-17.
Downloads
Published
How to Cite
Issue
Section
License
Copyright
The authors who publish in this journal agree to the following requirements:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)
Privacy Statement
The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.
